CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00127-07v1
14/8/1045    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caballero, Z. C.
Right arrow Articles by Umezawa, E. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caballero, Z. C.
Right arrow Articles by Umezawa, E. S.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, August 2007, p. 1045-1049, Vol. 14, No. 8
1071-412X/07/$08.00+0     doi:10.1128/CVI.00127-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Evaluation of Serological Tests To Identify Trypanosoma cruzi Infection in Humans and Determine Cross-Reactivity with Trypanosoma rangeli and Leishmania spp.{triangledown}

Zuleima C. Caballero,1,2 Octavio E. Sousa,2 Waldelania P. Marques,3 Amadeo Saez-Alquezar,3* and Eufrosina S. Umezawa1*

Instituto de Medicina Tropical de São Paulo (IMT) and Departamento de Medicina Preventiva da Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Enéas de Carvalho Aguiar 470, CEP 05403-000,1 Panel Assessoria & Controle de Qualidade, São Paulo, Brazil,3 Facultad de Medicina, Universidad de Panama, Panama City, Panama2

Received 19 March 2007/ Returned for modification 23 April 2007/ Accepted 14 May 2007

Five commercially available enzyme-linked immunosorbent assays (ELISAs), one in-house ELISA, and two hemagglutination assays were evaluated to determine their diagnostic accuracy for Chagas' disease in two studies. In study 1, ELISA kits showed 100% sensitivity, but specificities ranged from 82.84% to 100% when leishmaniasis cases were included and from 95.57% to 100% when leishmaniasis cases were excluded. Kits using recombinant antigens or synthetic peptides are more specific than those using crude extracts from Trypanosoma cruzi epimastigote forms. Kits evaluated in Panama, in study 2, showed 75% to 100% sensitivity and 97.12% to 100% specificity. These data were obtained by using a Western blot assay with T. cruzi trypomastigote excreted-secreted antigens as a reference test to confirm T. cruzi infection.

* Corresponding author. Mailing address for Eufrosina Setsu Umezawa: Av. Dr. Enéas de Carvalho Aguiar 470, CEP 05403-000, São Paulo, Brazil. Phone: 55 (11) 3061 7015. Fax: 55 (11) 3088 5237. E-mail: eumezawa{at}usp.br. Mailing address for Amadeo Saez-Alquezar: Rua Dr. Luís Migliano, 2050—Loja D, Morumbi, CEP 05711-001, São Paulo, Brazil. Phone: 55 (11) 3501 5101. Fax: 55 (11) 3501 0236. E-mail: amadeosaez{at}uol.com.br

{triangledown} Published ahead of print on 23 May 2007.

Clinical and Vaccine Immunology, August 2007, p. 1045-1049, Vol. 14, No. 8
1071-412X/07/$08.00+0     doi:10.1128/CVI.00127-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.